Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan

BACKGROUND: High-dose melphalan is of limited benefit as autologous stem-cell transplantation (ASCT) regimen for relapsed/refractory myeloma. Its poor results in this setting prompted us to study a new high-dose combination of infusional gemcitabine/busulfan/melphalan (Gem/Bu/Mel). METHODS: We condu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nieto, Yago, Valdez, Benigno C, Pingali, Sai R, Bassett, Roland, Delgado, Ruby, Nguyen, John, Shah, Nina, Popat, Uday, Jones, Roy B, Andersson, Borje S, Gulbis, Alison, Ahmed, Sairah, Bashir, Qaiser, Parmar, Simrit, Patel, Krina, Myers, Alan, Rondon, Gabriela, Orlowski, Robert Z, Champlin, Richard, Qazilbash, Muzaffar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844223/
https://www.ncbi.nlm.nih.gov/pubmed/28522110
http://dx.doi.org/10.1016/S2352-3026(17)30080-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844223/
https://www.ncbi.nlm.nih.gov/pubmed/28522110
http://dx.doi.org/10.1016/S2352-3026(17)30080-7

Ejemplares similares